These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36243666)

  • 41. Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT).
    Curran D; Matthews S; Rowley SD; Young JH; Bastidas A; Anagnostopoulos A; Barista I; Chandrasekar PH; Dickinson M; El Idrissi M; Heras I; Milliken ST; Monserrat Coll J; Navarro Matilla MB; Oostvogels L; Piątkowska-Jakubas B; Quiel D; Sabry W; Schwartz S; Selleslag DLD; Sullivan KM; Theunissen K; Yegin ZA; Yeh SP; Zaja F; Szer J;
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2474-2481. PubMed ID: 31394276
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness of vaccination against herpes zoster.
    de Boer PT; Wilschut JC; Postma MJ
    Hum Vaccin Immunother; 2014; 10(7):2048-61. PubMed ID: 25424815
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Budget-Impact Analysis of Alternative Herpes Zoster Vaccine Strategies: A U.S. HMO Perspective.
    Graham J; Mauskopf J; Kawai K; Johnson KD; Xu R; Acosta CJ
    J Manag Care Spec Pharm; 2016 Jul; 22(7):872-88. PubMed ID: 27348287
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults.
    Sanford M; Keating GM
    Drugs Aging; 2010 Feb; 27(2):159-76. PubMed ID: 20104941
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Rothberg MB; Virapongse A; Smith KJ
    Clin Infect Dis; 2007 May; 44(10):1280-8. PubMed ID: 17443464
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine.
    Pirrotta P; Tavares-Da-Silva F; Co M; Lecrenier N; Hervé C; Stegmann JU
    Drug Saf; 2021 Dec; 44(12):1341-1353. PubMed ID: 34622421
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.
    de Boer PT; Pouwels KB; Cox JM; Hak E; Wilschut JC; Postma MJ
    Vaccine; 2013 Feb; 31(9):1276-83. PubMed ID: 23306360
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults.
    Teng L; Mizukami A; Ng C; Giannelos N; Curran D; Sato T; Lee C; Matsuki T
    Dermatol Ther (Heidelb); 2022 Jun; 12(6):1447-1467. PubMed ID: 35668295
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Herpes Virus Infections in Kidney Transplant Patients (HINT) - a prospective observational cohort study.
    Hamm SR; Saini SK; Hald A; Vaaben AV; Pedersen NW; Suarez-Zdunek MA; Harboe ZB; Bruunsgaard H; Johansen IS; Larsen CS; Bistrup C; Birn H; Sørensen SS; Hadrup SR; Nielsen SD
    BMC Infect Dis; 2023 Oct; 23(1):687. PubMed ID: 37845608
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged ≥50 years in the United States.
    Florea A; Sy L; Qian L; Ackerson B; Luo Y; Wu J; Cheng Y; Ku J; Vega Daily L; Takhar H; Song J; Chmielewski-Yee E; Spence O; Seifert H; Oraichi D; Tseng HF
    Hum Vaccin Immunother; 2024 Dec; 20(1):2327145. PubMed ID: 38488143
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Herpes zoster subunit vaccine for the prevention of herpes zoster.
    Symoniak MR; Farrokh P; Gandhi MA; Slish JC
    Am J Health Syst Pharm; 2018 Jun; 75(12):861-869. PubMed ID: 29880523
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy.
    Volpi A; Boccalini S; Dari S; Clarke C; Curran D; Loiacono I; Pitrelli A; Puggina A; Tosatto R; Van Oorschot D; Franco E
    Hum Vaccin Immunother; 2020; 16(2):327-334. PubMed ID: 31442095
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-Effectiveness of the Recombinant Zoster Vaccine Among People Living With HIV in Japan.
    Sato S; Konishi T; Ohbe H; Yasunaga H
    Value Health Reg Issues; 2024 Jul; 44():101025. PubMed ID: 38970854
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A retrospective cohort study evaluating the incidence of herpes zoster and postherpetic neuralgia after a live attenuated Oka-strain herpes zoster vaccine in a real-world setting in Japan.
    Yaegashi M; Matsui H; Yoshida A; Ban H; Miyazaki R; Oda N; Hattori K; Motomura Y; Usami H; Matsushita H
    Vaccine; 2024 Jan; 42(3):464-470. PubMed ID: 38172019
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review.
    Kawai K; Preaud E; Baron-Papillon F; Largeron N; Acosta CJ
    Vaccine; 2014 Mar; 32(15):1645-53. PubMed ID: 24534737
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Potential cost-effectiveness of adjuvanted herpes zoster subunit vaccine for older adults in Hong Kong.
    You JHS; Ming WK; Lee CF; Tsang OT; Chan PK
    Vaccine; 2018 Jul; 36(31):4610-4620. PubMed ID: 29958739
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Determining the Optimal Vaccination Schedule for Herpes Zoster: a Cost-Effectiveness Analysis.
    Le P; Rothberg MB
    J Gen Intern Med; 2017 Feb; 32(2):159-167. PubMed ID: 27743284
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The landscape of herpes zoster management and prevention in the Philippines: Proceedings from two advisory boards.
    Panaligan M; Rosario MC; Zotomayor R; Zamora G; Lourdes Bibera G; Alejo AD; Javier J
    Hum Vaccin Immunother; 2023 Aug; 19(2):2263989. PubMed ID: 37853505
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status.
    Marin M; Yawn BP; Hales CM; Wollan PC; Bialek SR; Zhang J; Kurland MJ; Harpaz R
    Hum Vaccin Immunother; 2015; 11(5):1157-64. PubMed ID: 25806911
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vaccination for quality of life: herpes-zoster vaccines.
    Lang PO; Aspinall R
    Aging Clin Exp Res; 2021 Apr; 33(4):1113-1122. PubMed ID: 31643072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.